Biewanga et al developed a score for predicting disease-specific survival for a patient with early stage cervical cancer. This can help to identify a patient who may benefit from more aggressive management. The authors are from the Academic Medical Center in Amsterdam.
Patient selection: FIGO Stage IA2 to IIA.
Parameter:
(1) histologic features
(2) tumor diameter in mm
(3) depth of stromal invasion in percent
(4) lymph node metastases
(5) parametrial extension
(6) lymphovascular space invasion
Parameter |
Finding |
Points |
---|---|---|
histology |
squamous |
0 |
|
adenosquamous |
1 |
|
adenocarcinoma |
4 |
tumor diameter |
< 20 mm |
0 |
|
20 to 60 mm |
1 |
|
> 60 mm |
4 |
depth of stromal invasion |
< 33% |
0 |
|
33 to 67% |
1 |
|
> 67% |
3 |
lymph node metastases |
no |
0 |
|
yes |
3 |
parametrial nvasion |
no |
0 |
|
yes |
3 |
lymphovascular space invasion |
no |
0 |
|
yes |
2 |
total score =
= SUM(points for all 6 parameters)
Interpretation:
• minimum score: 0
• maxium score: 19
• The higher the score the worse the prognosis.
Score |
Estimated 5-Year Disease-Specific Survival |
---|---|
0 or 1 |
> 99% |
2 to 8 |
(-0.1429 * ((score)^2)) + (0.4929 * (score)) + 98.48 |
9 to 16 |
(-0.8650 * ((score)^2)) + (12.81 * (score)) + 45.38 |
17 to 19 |
< 25% |
Purpose: To predict the prognosis for a woman with an early stage cervical cancer using the score of Biewenga et al.
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
Objective: severity, prognosis, stage
ICD-10: C53,